Showing 4771-4780 of 7240 results for "".
- Sarecycline Monotherapy Delivers in Real-World Acne Studyhttps://practicaldermatology.com/news/sarecycline-monotherapy-delivers-in-real-world-acne-study/2484121/A post hoc analysis of the PROSES study found that oral sarecycline monotherapy is as effective as combination therapy with topicals in treating moderate-to-severe acne vulgaris (AV), based on 12-week outcomes from a real-world U.S. cohort presented by Dr. Hilary B
- 487-GEP Test Identifies Optimal Systemic Therapy for ADhttps://practicaldermatology.com/news/487-gep-test-identifies-optimal-systemic-therapy-for-ad/2484115/A 487-gene expression profile (487-GEP) test may help personalize systemic therapy selection for patients with atopic dermatitis (AD), according to results from a prospective, multicenter trial presented by Dr. Jonathan Silverberg et al at the 2025 Fall Clinical De
- Dr. James Del Rosso Presents 'Medicine Chest' at Fall Clinicalhttps://practicaldermatology.com/news/dr-james-del-rossos-presents-medicine-chest-at-fall-clinical/2484096/A curated overview of skincare fundamentals, treatment pearls, and emerging data across acne, rosacea, hyperpigmentation, hidradenitis suppurativa (HS), and more was on display as James Q. Del Rosso, DO, presented “What’s New in the Medicine Chest” at the 2025 Fall Clinical Dermatology Conference
- JAK Inhibition, Durable Repigmentation Strategies Among Vitiligo Advanceshttps://practicaldermatology.com/news/jak-inhibition-durable-repigmentation-strategies-among-vitiligo-advances/2484093/Vitiligo has entered a new era of treatment innovation, according to Seemal Desai, MD, FAAD, who presented “Vitiligo Spotlight: A Closer Look at JAK Inhibitors” at the 2025 Fall Clinical Dermatology Conference. Dr. Desai characterized the current moment as a “Renaissance period” in vitilig
- New Deuruxolitinib Data Show It Meets 'The Need for Speed'https://practicaldermatology.com/news/new-deuruxolitinib-data-show-it-meets-the-need-for-speed/2484089/Deuruxolitinib resulted in significant hair regrowth starting at Week 8, continually improving through Week 24, and the 8-mg and 12-mg BID doses showed significant efficacy vs placebo across subgroups, according to new data presented at the 2025 Fall Clinical Dermatology Conference. Other
- Long-Term Baricitinib Data Reinforce Potential in Adolescents With AAhttps://practicaldermatology.com/news/long-term-baricitinib-data-reinforce-potential-in-adolescents-with-aa/2484088/More than half of adolescents treated for alopecia areata (AA) with baricitinib 4mg achieved successful scalp hair response by Week 52, with a response rate reaching 71% among those with baseline Severity of Alopecia Tool (SALT) score of 50-94, according to new data presented at the 2025 Fall Cli
- IL-17A Inhibitors Linked with Scalp and Gut Microbiota Improvement in Psoriasis Patientshttps://practicaldermatology.com/news/il-17a-inhibitors-linked-with-scalp-and-gut-microbiota-improvement-in-psoriasis-patients/2484034/Treatment with IL-17A inhibitors may help rebalance disrupted scalp and gut microbiota in patients with moderate-to-severe psoriasis vulgaris, according to a new study. Researchers collected scalp and fecal samples from 15 adu
- Dr. Woolery-Lloyd Appointed Program Development Advisor for Skin of Color Updatehttps://practicaldermatology.com/news/dr-woolery-lloyd-appointed-program-development-advisor-for-skin-of-color-update/2484015/Heather Woolery-Lloyd, MD, FAAD, has been appointed program development advisor for Skin of Color Update, the nation’s largest medical education event focused on dermatologic care for patients with skin of color. Dr. Woolery-Lloyd serves as director of the Skin of Color Division at the Uni
- Study Links Structural and Immune Risk Factors to Skin Conditions in PWHhttps://practicaldermatology.com/news/study-links-structural-and-immune-risk-factors-to-skin-conditions-in-pwh/2483949/Nearly half of people living with HIV (PWH) are diagnosed with at least one dermatologic condition despite advances in antiretroviral therapy (ART), according to a longitudinal cohort study published through the DC Cohort. Accor
- Pfizer and GWU Renew Grant Program to Expand Teledermatology Access for Inflammatory Skin Conditionshttps://practicaldermatology.com/news/pfizer-and-gwu-renew-grant-program-to-expand-teledermatology-access-for-inflammatory-skin-conditions/2483889/Pfizer Global Medical Grants and The George Washington University (GWU) have renewed their joint grant program focused on broadening access to dermatologic care in underserved U.S. communities. According to a GWU press announc